Multiparameter flow cytometry as a powerful tool in drug development

Who may this interest?

• Translational scientists
• Bioanalytic scientists
• Clinical pharmacologists
• Individuals working in clinical operations

Speakers

Lynn Kamen Ph.D.
Scientific Officer and Executive Director
BioAgilytix (NC, USA)

Lynn Kamen is a Scientific Officer at BioAgilytix (NC, USA). She earned her Ph.D. in Immunology at the University of Michigan (MI, USA) and completed a postdoctoral fellowship in Immunology at the University of California San Francisco (CA, USA). Lynn has over a decade of experience working in drug development, from early target discovery through to clinical development for both large and small molecules at several companies, including Portola Pharmaceuticals and Alector (both CA, USA). More recently, Lynn was a Principal Scientist at Genentech (CA, USA), where she supported the in vitro biological characterization of large molecules and led the development of immunogenicity assays, including anti-drug antibody (ADA), neutralizing antibody (NAb), and immunogenicity risk-ranking assays. She is the co-lead of the AAPS NAber working group and member of the AAPS NAb drug tolerance sub-team.

Michael A Podolsky Ph.D.
Manager I
BioAgilytix

Michael Podolsky serves as the Manager of the Flow Cytometry and Cell-Based Assays group at BioAgilytix Boston. He earned his Ph.D. in Immunology and Infectious Diseases at The Pennsylvania State University (PA, USA) where he studied the interactions of T and B lymphocytes in cutaneous tumors. As a postdoctoral fellow at the Children’s Hospital of Philadelphia (PA, USA), he studied B cell development and leukemia generation. In his 12 years in the field, Michael has developed and implemented assays for cell development, phenotyping and functionality using a variety of techniques across multiple technologies. Michael’s team uses flow cytometry among other platforms to assess the efficacy and safety of emerging therapeutics under good practice (GxP) regulations.

Jing Yu MS
Manager I
BioAgilytix

Jing joined BioAgilytix in 2021 as a Manager on the cell-based team and has more than 15 year’s of experience in flow cytometry. Over the past eight years, she has worked in CRO labs leading flow cytometry assay development, optimization and validation to support many clinical trials. Jing holds ASCP certifications in Molecular Biology, Flow Cytometry, Histology, and Immunohistochemistry and received her M.S. degree from Oklahoma State University (OK, USA).

Aaron Ochel Ph.D.
Principal Investigator
BioAgilytix

Aaron earned his Ph.D. from Helmholtz Center for Infection Research/ University of Braunschweig (both: Braunschweig, Germany).  He joined BioAgilytix in 2020 as an Associate Principal Investigator and is responsible for scientific project management including method development, assay qualification, and validation of cell-based assays to measure immune responses against drugs and in response to drug treatment. He is also the primary contact for sponsor communication. Aaron has published peer-reviewed articles on cellular immunology to understand and decipher the causes of acute and chronic inflammation.